

Amendments to the Claims:

Please cancel Claim 116. Please amend Claims 91, 100, 102, 104, 106, 108, 110, 112, 114 and 117. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing:

1-90. (Canceled)

91. (Currently amended) A method of improving memory consolidation in a human ~~having an impairment in memory consolidation~~, comprising the step of administering an amphetamine to a [[the]] human ~~having an impairment in memory consolidation~~ in an amount effective to improve memory consolidation in the human, wherein the amphetamine is administered as a component of a composition that includes at least about 90 mole percent l-amphetamine relative to the total amphetamine content of the composition.
92. (Previously presented) The method of Claim 91, wherein the amphetamine is administered in a single dose.
93. (Previously presented) The method of Claim 92, wherein the single dose is a dose between about a 0.0001 mg/kg dose to about a 4.0 mg/kg dose.
94. (Previously presented) The method of Claim 93, wherein the dose is between about a 0.0001 mg/kg dose to about a 1 mg/kg dose.
95. (Previously presented) The method of Claim 92, wherein the single dose is a dose between about a 2.5 mg dose to about a 125 mg dose.

96. (Previously presented) The method of Claim 91, wherein the amphetamine is administered in multiple doses.
97. (Previously presented) The method of Claim 96, wherein each dose of the multiple doses is administered at a dose between about a 0.0001 mg/kg dose to about a 4.0 mg/kg dose.
98. (Previously presented) The method of Claim 97, wherein the dose is between about a 0.0001 mg/kg dose to about a 1 mg/kg dose.
99. (Previously presented) The method of Claim 96, wherein each dose of the multiple doses is administered at a dose between about a 2.5 mg dose to about a 125 mg dose.
100. (Currently Amended) A method of improving memory consolidation in a human ~~having an impairment in memory consolidation~~, comprising the step of administering an amphetamine to a ~~[[the]]~~ human having an impairment in memory consolidation in an amount effective to improve memory consolidation in the human, wherein the amphetamine is administered as a component of a composition that includes at least about 95 mole percent l-amphetamine relative to the total amphetamine content of the composition.
101. (Previously presented) The method of Claim 100, wherein the amphetamine is administered in multiple doses.
102. (Currently Amended) A method of improving memory consolidation in a human ~~having an impairment in memory consolidation~~, comprising the step of administering an amphetamine to a ~~[[the]]~~ human having an impairment in memory consolidation in an amount effective to improve memory consolidation in the human, wherein the amphetamine is administered as a component of a composition that includes at least about 99 mole percent l-amphetamine relative to the total amphetamine content of the composition.

103. (Previously presented) The method of Claim 102, wherein the amphetamine is administered in multiple doses.
104. (Currently Amended) A method of improving memory consolidation in a human ~~having an impairment in memory consolidation~~, comprising the step of administering an amphetamine to a a [[the]] human ~~having an impairment in memory consolidation~~ in an amount effective to improve memory consolidation in the human, wherein the amphetamine is administered as a component of a composition that includes at least about 90 mole percent l-amphetamine relative to the total amphetamine content of the composition and the dose of l-amphetamine administered to the human is from between about a 0.0001 mg/kg dose to about a 4.0 mg/kg dose.
105. (Previously presented) The method of Claim 104, wherein the amphetamine is administered in multiple doses.
106. (Currently Amended) A method of improving memory consolidation in a human ~~having an impairment in memory consolidation~~, comprising the step of administering an amphetamine to a a [[the]] human ~~having an impairment in memory consolidation~~ in an amount effective to improve memory consolidation in the human, wherein the amphetamine is administered as a component of a composition that includes at least about 90 mole percent l-amphetamine relative to the total amphetamine content of the composition and the dose of l-amphetamine administered to the human is from between about a 2.5 mg dose to about a 125 mg dose.
107. (Previously presented) The method of Claim 106, wherein the amphetamine is administered in multiple doses.
108. (Currently Amended) A method of improving memory consolidation in a human ~~having an impairment in memory consolidation~~, comprising the step of administering an amphetamine to a a [[the]] human ~~having an impairment in memory consolidation~~ in an

amount effective to improve memory consolidation in the human, wherein the amphetamine is administered as a component of a composition that includes at least about 95 mole percent l-amphetamine relative to the total amphetamine content of the composition and the dose of l-amphetamine administered to the human is from between about a 0.0001 mg/kg dose to about 4.0 mg/kg dose.

109. (Previously presented) The method of Claim 108, wherein the amphetamine is administered in multiple doses.
110. (Currently Amended) A method of improving memory consolidation in a human ~~having an impairment in memory consolidation~~, comprising the step of administering an amphetamine to a [[the]] human having an impairment in memory consolidation in an amount effective to improve memory consolidation in the human, wherein the amphetamine is administered as a component of a composition that includes at least about 95 mole percent l-amphetamine relative to the total amphetamine content of the composition and the dose of l-amphetamine administered to the human is from between about a 2.5 mg dose to about a 125 mg dose.
111. (Previously presented) The method of Claim 110, wherein the amphetamine is administered in multiple doses.
112. (Currently Amended) A method of improving memory consolidation in a human ~~having an impairment in memory consolidation~~, comprising the step of administering an amphetamine to a [[the]] human having an impairment in memory consolidation in an amount effective to improve memory consolidation in the human, wherein the amphetamine is administered as a component of a composition that includes at least about 99 mole percent l-amphetamine relative to the total amphetamine content of the composition and the dose of l-amphetamine administered to the human is from between about a 0.1 mg/kg dose to about 4.0 mg/kg dose.

113. (Previously presented) The method of Claim 112, wherein the amphetamine is administered in multiple doses.
114. (Currently Amended) A method of improving memory consolidation in a human ~~having an impairment in memory consolidation~~, comprising the step of administering an amphetamine to a ~~[[the]]~~ human having an impairment in memory consolidation in an amount effective to improve memory consolidation in the human, wherein the amphetamine is administered as a component of a composition that includes at least about 99 mole percent l-amphetamine relative to the total amphetamine content of the composition and the dose of l-amphetamine administered to the human is from between about a 2.5 mg dose to about a 125 mg dose.
115. (Previously presented) The method of Claim 114, wherein the amphetamine is administered in multiple doses.
116. (Canceled)
117. (Currently amended) A method of improving memory consolidation in a human ~~having an impairment in memory consolidation~~, comprising the steps of:
- a) assessing the degree of impairment in memory consolidation in a ~~[[the]]~~ human having an impairment in memory consolidation;
 - b) administering an amphetamine to the human having an impairment in memory consolidation in an amount effective to improve memory consolidation in the human, wherein the amphetamine is administered as a component of a composition that includes at least between about 90 mole percent l-amphetamine relative to the total amphetamine content of the composition ~~to about 99 mole percent l-amphetamine~~; and
 - ~~[[b)]]~~ c) determining the improvement in memory consolidation after administering the amphetamine to the human having an impairment in memory consolidation.

118. (Previously presented) The method of Claim 117, further including the step of comparing the impairment in memory consolidation in the human before administering the amphetamine to the improvement in memory consolidation in the human after administering the amphetamine.
119. (Previously presented) The method of Claim 117, wherein the amphetamine is administered in multiple doses.